Oligometastatic survivorship is outgrowing traditional oncology follow-up models

KEY POINTS

• This review examines a consequence of increasingly successful metastasis-directed treatment that receives far less attention than local control: some patients with metastatic cancer now live for years with repeatedly treated, durably controlled disease but fit poorly into either conventional curative survivorship or palliative-care pathways.
• The authors emphasize that oligometastatic disease is not a fixed state. The ESTRO/EORTC framework distinguishes genuine from induced oligometastatic disease, de novo from repeat disease and synchronous from metachronous presentation, alongside oligorecurrence, oligoprogression and oligopersistence. Patients can move between these states repeatedly over years.
• The clinical rationale for this emerging survivorship population is supported by metastasis-directed therapy trials. In SABR-COMET, selected patients receiving SABR to all metastatic lesions achieved 42% five-year overall survival versus 17% with standard care, demonstrating that metastatic disease can sometimes behave as a long-term controlled condition rather than a short terminal phase.
• Better imaging is simultaneously identifying more patients eligible for local treatment. PET/CT, PSMA PET, whole-body MRI and MR-guided radiotherapy are refining disease detection and selection, while circulating tumor DNA, circulating tumor cells, genomic profiling and radiomics may eventually add biological selection. However, the review notes that no biomarker is currently validated for routine selection for metastasis-directed treatment.
• Longer survival does not mean absence of morbidity. Repeated SABR, surgery and systemic treatment can accumulate fatigue, pain, cognitive impairment, psychological distress, functional limitations, sexual problems and financial toxicity, while recurrent surveillance and repeated treatment cycles create persistent uncertainty around future progression.
• The authors cite estimates that approximately 8% of people living with cancer in England have treatable but incurable disease, illustrating the broader population potentially falling between traditional follow-up structures. Yet no evidence-based survivorship pathway has been developed specifically for oligometastatic disease.
• The proposed solution is supportive oncology integrated throughout treatment, not introduced only near the end of life. Suggested components include routine patient-reported outcome monitoring, prehabilitation and rehabilitation, exercise and nutritional interventions, psychological and sexual-health support, late-toxicity surveillance, vocational support and coordinated follow-up between oncology, primary care and allied health professionals. The authors explicitly distinguish this model from specialist palliative care.

CLINICAL TAKEAWAY

SOURCE

Cancers